Chronic sinusitis, officially known as chronic rhinosinusitis (CRS), is a common yet under-recognized chronic inflammatory disease of the paranasal sinuses affecting approximately 5% of the Canadian population. Aside from gaining a reputation for its detrimental effects on patient quality-of-life (QoL) and daily productivity, CRS is associated with a lifetime of medical and surgical resource consumption resulting in significant health care expenditure. The estimated direct cost of CRS to the Canadian health care system is $990 million per year, which is comparable to the annual direct costs of asthma. The large economic burden of chronic sinusitis provides a strong incentive to improve both the quality and value of care for this chronic inflammatory disease.